Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States

    Mark Ray, Elyse Swallow, Kavita Gandhi, Christopher Carley, Vanja Sikirica, Travis Wang, Nicolae Done, James Signorovitch, Arash Mostaghimi
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls. Our plain-language summary of this paper — not a Tressless recommendation.
    This study assessed healthcare resource utilization (HCRU) and direct healthcare costs for US adolescents with alopecia areata (AA), including alopecia totalis (AT) and universalis (AU). Using IBM MarketScan® databases, 130 AT/AU adolescents and 1105 non-AT/AU adolescents were compared to matched controls. Results showed that AT/AU patients had significantly more outpatient and dermatologist visits, higher mean plan costs ($9397 vs $2267), and higher out-of-pocket costs ($2081 vs $751) compared to controls. Non-AT/AU patients also had higher HCRU and costs than controls. The study concluded that adolescents with AA, especially those with AT/AU, incur substantial incremental healthcare costs, highlighting the significant economic burden of AA on patients and health plans.
    Discuss this study in the Community →

    Research cited in this study

    15 / 15 results